alpha 1-proteinase inhibitor, human 1 MG Injection

RxCUI
1661208
RxNorm name
alpha 1-proteinase inhibitor, human 1 MG Injection
Display name
alpha 1-proteinase inhibitor, human 1 MG Injection
Full name
alpha 1-proteinase inhibitor, human 1 MG Injection
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:06

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125078ZemairaAlpha-1-Proteinase Inhibitor (Human)351(a)Rx2026-10-01
103174prolastin,prolastin-c,prolastin-c liquidAlpha-1-Proteinase Inhibitor (Human)351(a)Rx2026-10-01
125039Aralast, Aralast NpAlpha-1-Proteinase Inhibitor (Human)351(a)Rx2026-10-01
125325GlassiaAlpha-1-Proteinase Inhibitor (Human)351(a)Rx2026-10-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 4 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Prolastin-C LiquidALPHA1-PROTEINASE INHIBITOR (HUMAN)GRIFOLS USA, LLC2b620e6b-6a24-0957-1288-ae529c4cc3a22026-11-01Warnings, Adverse reactionsExact identifier
rxcui: 1661208
GLASSIAALPHA.1-PROTEINASE INHIBITOR HUMANTakeda Pharmaceuticals America, Inc.83473cbb-48e4-42a2-81b6-4c851423da7b2025-12-02Warnings, Adverse reactionsExact identifier
rxcui: 1661208
Aralast NPALPHA-1-PROTEINASE INHIBITOR (HUMAN)Takeda Pharmaceuticals America, Inc.a9a5b46e-04da-41bd-bb5f-c4936b664fef2025-11-25Warnings, Adverse reactionsExact identifier
rxcui: 1661208
ZemairaALPHA-1-PROTEINASE INHIBITOR HUMANCSL Behring LLC0c3354b5-a1d8-4f98-ad55-2eafe4265c4e2024-09-23Warnings, Adverse reactionsExact identifier
rxcui: 1661208

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 6 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
83473cbb-48e4-42a2-81b6-4c851423da7balpha 1-proteinase inhibitor, human 1 MG Injection [PSN] · alpha 1-proteinase inhibitor, human 1 MG Injection [SCD]231These highlights do not include all the information needed to use GLASSIA safely and effectively. See full prescribing information for GLASSIA. GLASSIA ® (Alpha 1 -Proteinase Inhibitor (Human)) Injection, For Intravenous Use Initial U.S. Approval: 201020251202
0c3354b5-a1d8-4f98-ad55-2eafe4265c4ealpha 1-proteinase inhibitor, human 1 MG Injection [PSN] · alpha 1-proteinase inhibitor, human 1 MG Injection [SCD]227These highlights do not include all the information needed to use ZEMAIRA safely and effectively. See full prescribing information for ZEMAIRA. ZEMAIRA ® (alpha 1 -proteinase inhibitor (human)) lyophilized powder for reconstitution for intravenous use Initial U.S. Approval: 200320240923
91edab72-c889-470e-8315-1798b5548dcaalpha 1-proteinase inhibitor, human 1 MG Injection [PSN] · alpha 1-proteinase inhibitor, human 1 MG Injection [SCD]225These highlights do not include all the information needed to use PROLASTIN ® -C safely and effectively. See full prescribing information for PROLASTIN-C. PROLASTIN ® -C (Alpha 1 -Proteinase Inhibitor [Human]) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 198720220225
a9a5b46e-04da-41bd-bb5f-c4936b664fefalpha 1-proteinase inhibitor, human 1 MG Injection [PSN] · alpha 1-proteinase inhibitor, human 1 MG Injection [SCD]220These highlights do not include all the information needed to use ARALAST NP safely and effectively. See full prescribing information for ARALAST NP. ARALAST ® NP (Alpha 1 -Proteinase Inhibitor (Human)) For Intravenous Use. Lyophilized Powder for Solution for Injection Initial U.S. Approval: 200220251125
2b620e6b-6a24-0957-1288-ae529c4cc3a2alpha 1-proteinase inhibitor, human 1 MG Injection [PSN] · alpha 1-proteinase inhibitor, human 1 MG Injection [SCD]214These highlights do not include all the information needed to use PROLASTIN-C LIQUID safely and effectively. See full prescribing information for PROLASTIN-C LIQUID. PROLASTIN-C LIQUID (Alpha 1 -Proteinase Inhibitor [Human]) Solution for Intravenous Injection Initial U.S. Approval: 198720220705
31a53b86-857b-a2d9-e063-6394a90abfb8alpha 1-proteinase inhibitor, human 1 MG Injection [PSN] · alpha 1-proteinase inhibitor, human 1 MG Injection [SCD]2120250331